Canaccord Genuity started coverage on shares of Antibe Therapeutics (OTCMKTS:ATBPF) in a research report released on Monday, TipRanks reports. The firm issued a buy rating and a $1.50 price objective on the stock.
Separately, restated a sell rating on shares of Antibe Therapeutics in a report on Tuesday, June 9th.
OTCMKTS ATBPF opened at $0.31 on Monday. Antibe Therapeutics has a 52-week low of $0.25 and a 52-week high of $0.64. The stock’s 50-day moving average is $0.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.43. The stock has a market capitalization of $96.69 million, a P/E ratio of -5.25 and a beta of 0.25.
Antibe Therapeutics (OTCMKTS:ATBPF) last posted its quarterly earnings data on Friday, July 24th. The company reported ($0.02) earnings per share (EPS) for the quarter. Antibe Therapeutics had a negative return on equity of 269.39% and a negative net margin of 193.09%. The company had revenue of $1.75 million for the quarter.
About Antibe Therapeutics
Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.
Recommended Story: What is channel trading?
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.